SwitzerlandDec. 28, 2025 4:09 AM ETNovartis AG (NVS) StockAgar Capital2.69K FollowersComments(2)SummaryNovartis (NVS) offers visible earnings, stable margins, and low volatility, making it attractive amid market focus on high-growth AI plays.NVS's diversified portfolio—Oncology, Cardiovascular, Immunology, Neuroscience, and Established Medicines—balances high-margin innovation with stable, repeatable revenues.Patent cliff fears are mitigated by volume growth from new therapies and a robust pipeline across key therapeutic areas.International exposure from NVS provides valuable geographic diversification for U.S.-centric portfolios.Lock Stock/DigitalVision via Getty ImagesThesisCapital is flocking to a few high-growth AI plays and ignoring other opportunities because of the AI trend in the markets. The fear of a patent cliff (loss of revenue from a drug going off-patent) forThis article was written byAgar Capital2.69K FollowersI’m a Portfolio manager (flexible equity funds and private clients), fundamental equity research, macro and geopolitical strategy.Over 10 years across global markets, managing multi-asset strategies and equity portfolios at a European asset manager.I combine top-down macro, bottom-up stock selection and real-time positioning (Bloomberg, models, data).I focus on earnings, tech disruption, policy shifts and capital flows — to identify mispriced opportunities before the market.On Seeking Alpha I share high-conviction ideas, contrarian views and deep breakdowns of both growth and value names.For more insights: follow me on X @AgarCapitalAnalyst’s Disclosure:I/we have a beneficial long position in the shares of NVS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Comments(2)